MediWound Ltd. (MDWD) Stock Price

MDWDStock

$12.66−24.73%52W

Market Cap$163.44M

P/E—

PEG Ratio—

Div yield—

Beta0.09

MDWD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.88%

Price vs S&P 500 (4W)-12.51%

VGM Score31.82

Book Value / Share (Quarterly)$3.22

P/TBV (Annual)5.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-13.82%

Cash Flow / Share (Quarterly)$-1.96

Price vs S&P 500 (YTD)-44.24%

Gross Margin (TTM)19.61%

Net Profit Margin (TTM)-180.30%

EPS (TTM)$-2.26

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-2.26

Revenue Growth (5Y)-4.86%

EPS (Annual)$-2.10

ROI (Annual)-45.56%

Gross Margin (Annual)19.19%

Net Profit Margin (5Y Avg)-91.44%

Cash / Share (Quarterly)$3.47

Revenue Growth QoQ (YoY)-62.71%

ROA (Last FY)-27.68%

Revenue Growth TTM (YoY)-24.64%

EBITD / Share (TTM)$-2.20

ROE (5Y Avg)-95.84%

Operating Margin (TTM)-193.53%

Cash Flow / Share (Annual)$-1.68

P/B Ratio4.20x

P/B Ratio (Quarterly)5.00x

Net Income / Employee (Annual)$-197,300

EV / Revenue (TTM)9.48x

Net Interest Coverage (TTM)-12.46x

ROA (TTM)-31.87%

EV / EBITDA (TTM)19.56x

EPS Incl Extra (Annual)$-2.10

Current Ratio (Annual)2.33x

Quick Ratio (Quarterly)2.19x

3-Month Avg Trading Volume0.08M

52-Week Price Return-24.73%

Revenue / Employee (TTM)$119,700

Tangible BV / Share (Quarterly)$3.22

P/S Ratio (Annual)10.25x

Asset Turnover (Annual)0.20x

52-Week High$20.30

Operating Margin (5Y Avg)-81.10%

EPS Excl Extra (Annual)$-2.10

CapEx CAGR (5Y)43.02%

Tangible BV CAGR (5Y)24.22%

26-Week Price Return-27.95%

Quick Ratio (Annual)2.16x

13-Week Price Return-13.05%

Total Debt / Equity (Annual)0.20x

Current Ratio (Quarterly)2.41x

Enterprise Value$137.28M

Revenue / Share Growth (5Y)-23.24%

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-2.71%

Revenue / Employee (Annual)$140,200

Inventory Turnover (Annual)4.04x

Pretax Margin (Annual)-139.81%

Cash / Share (Annual)$4.14

3-Month Return Std Dev33.17%

Gross Margin (5Y Avg)27.60%

Net Income / Employee (TTM)$-215,700

ROE (Last FY)-54.73%

Net Interest Coverage (Annual)-0.83x

EPS Basic Excl Extra (Annual)$-2.10

Receivables Turnover (TTM)3.65x

Total Debt / Equity (Quarterly)0.20x

EPS Incl Extra (TTM)$-2.26

Receivables Turnover (Annual)5.28x

ROI (TTM)-55.56%

P/S Ratio (TTM)12.00x

Pretax Margin (5Y Avg)-90.90%

Revenue / Share (Annual)$1.49

Tangible BV / Share (Annual)$3.40

Price vs S&P 500 (52W)-43.29%

Year-to-Date Return-31.42%

5-Day Price Return-2.62%

EPS Normalized (Annual)$-2.10

ROA (5Y Avg)-37.35%

Net Profit Margin (Annual)-140.80%

Month-to-Date Return-10.34%

Cash Flow / Share (TTM)$-1.35

EBITD / Share (Annual)$-2.12

Operating Margin (Annual)-148.98%

LT Debt / Equity (Annual)7.75x

ROI (5Y Avg)-79.59%

LT Debt / Equity (Quarterly)17.96x

EPS Basic Excl Extra (TTM)$-2.26

P/TBV (Quarterly)5.00x

P/B Ratio (Annual)5.42x

Inventory Turnover (TTM)2.79x

Pretax Margin (TTM)-179.28%

Book Value / Share (Annual)$3.40

Price vs S&P 500 (13W)-15.00%

Beta0.09x

P/FCF (Annual)23.17x

Revenue / Share (TTM)$1.12

ROE (TTM)-67.22%

52-Week Low$12.52

vGradeC

gGradeF

mGradeD

vgmGradeD

MDWD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.77	-$0.57	+25.97%(+$0.20)
Q1 2026	May 27, 2026	-$0.66	-$0.23	+65.26%(+$0.43)
Q4 2025	Mar 5, 2026	-$0.61	-$0.56	+8.50%(+$0.05)
Q3 2025	Nov 20, 2025	-$0.83	-$0.24	+71.01%(+$0.59)
Q2 2025	Aug 14, 2025	-$0.57	-$1.23	-116.55%(-$0.66)

MDWD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.17

Industry Peers — Pharmaceutical Preparations(21)

Symbol	Value Score	Growth Score	Momentum Score	Price
MDWDMediWound Ltd.	C	F	D	$12.66
DFTXDefinium Therapeutics, Inc. Common Shares	—	—	A	$40.98
RGCRegencell Bioscience Holdings Limited Ordinary Shares	—	—	D	$5.50
TRLVTrulieve Cannabis Corp.	B	C	A	$11.82
CRONCronos Group Inc. Common Share	C	B	B	$3.38
GLASGlass House Brands Inc.	C	C	C	$9.88
TLRYTilray Brands, Inc. Common Stock	B	B	D	$4.59
CGCCanopy Growth Corporation Common Shares	B	C	D	$1.00
SNDLSundial Growers Inc. Common Shares	A	C	D	$1.35
NAGENiagen Bioscience, Inc. Common Stock	C	C	D	$3.29
USNAUSANA Health Sciences Inc	B	D	D	$14.04
ACBAurora Cannabis Inc. Common Shares	B	D	C	$4.01
FTLFFitLife Brands, Inc. Common Stock	B	C	D	$9.79
BTMDBiote Corp. Class A Common Stock	A	D	D	$1.57
NAIINatural Alternatives International Inc.	A	C	D	$2.16
MTEXMannatech Inc.	B	D	B	$6.74
BONBon Natural Life Limited Class A Ordinary Shares	B	D	C	$1.14
AKANAkanda Corp. Common Shares	C	F	D	$3.89
IMCCIM Cannabis Corp. Common Shares	A	B	F	$3.41
SNYRSynergy CHC Corp. Common Stock	A	C	F	$0.10
MEHAFunctional Brands, Inc. Common Stock	A	C	D	$0.01
TRUUVanEck Utilities TruSector ETF	—	—	C	$23.37

About MediWound Ltd.

MediWound Ltd is a biopharmaceutical company developing treatments for severe burns and hard-to-heal wounds. Its lead product, NexoBrid, is FDA-approved for eschar removal in severe burns and offers a non-surgical alternative to conventional debridement. The company is advancing a pipeline including EscharEx for chronic wound debridement and MW005 for non-melanoma skin cancer, with revenue primarily generated in the United States.